|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15551556155715581559156015611562156315641565...15771578» |
- | crenolanib (ARO-002) / AROG
Enrollment closed, Stroma, Metastases: Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene (clinicaltrials.gov) - Dec 30, 2013
P2, N=20, Active, not recruiting, Sponsor: Arog Pharmaceuticals LLC
Recruiting --> Active, not recruiting
- methotrexate IV / Generic mfg.
New P2 trial, Adverse events: Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays? (clinicaltrials.gov) - Dec 25, 2013
P2, N=38, Recruiting, Sponsor: University College, London
- | Avastin (bevacizumab) / Roche
New P1 trial, Metastases: Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (clinicaltrials.gov) - Dec 23, 2013
P1, N=18, Recruiting, Sponsor: Mayo Clinic
- patritumab (U3-1287) / Amgen, Daiichi Sankyo
Trial termination, Metastases: Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Dec 18, 2013
P1, N=12, Terminated, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Recruiting --> Terminated; treatment was not working
- patritumab (U3-1287) / Amgen, Daiichi Sankyo
Enrollment change, Metastases: Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Dec 18, 2013
P1, N=12, Terminated, Sponsor: Washington University School of Medicine
Recruiting --> Terminated; treatment was not working N=25 --> 12
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open: Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors (clinicaltrials.gov) - Dec 18, 2013
P1, N=30, Recruiting, Sponsor: Merrimack Pharmaceuticals
N=25 --> 12 Not yet recruiting --> Recruiting
- Caprelsa (vandetanib) / Sanofi
New P2 trial, Stroma: Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Dec 17, 2013
P2, N=27, Recruiting, Sponsor: National Cancer Institute (NCI)
- leucovorin calcium / Generic mfg.
New P1 trial, Combination therapy: Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas (clinicaltrials.gov) - Dec 17, 2013
P1, N=39, Not yet recruiting, Sponsor: City of Hope Medical Center
- | IDC-G305 / Merck (MSD)
New P1 trial, Metastases: A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer (clinicaltrials.gov) - Dec 17, 2013
P1, N=30, Recruiting, Sponsor: Immune Design
- IDC-G305 / Merck (MSD)
Enrollment open, Metastases: A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer (clinicaltrials.gov) - Dec 17, 2013
P1, N=30, Recruiting, Sponsor: Immune Design
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Trial completion: Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma (clinicaltrials.gov) - Dec 17, 2013
P2, N=56, Completed, Sponsor: Duke University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Trial completion: PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma (clinicaltrials.gov) - Dec 17, 2013
P=N/A, N=70, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed Recruiting --> Completed
- thalidomide / Generic mfg.
Trial completion: Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus (clinicaltrials.gov) - Dec 17, 2013
P2, N=51, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- | Korlym (mifepristone) / Corcept Therap
New P1 trial, Combination therapy, Metastases: Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors (clinicaltrials.gov) - Dec 16, 2013
P1, N=40, Recruiting, Sponsor: Corcept Therapeutics
- Caprelsa (vandetanib) / Sanofi
Enrollment closed, Combination therapy: A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas (clinicaltrials.gov) - Dec 16, 2013
P2, N=112, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Yervoy (ipilimumab) / BMS
Enrollment change, Combination therapy, Surgery, Stroma, Metastases: Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic (clinicaltrials.gov) - Dec 15, 2013
P1, N=39, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=30 --> 39
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P1 trial: Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors (clinicaltrials.gov) - Dec 15, 2013
P1, N=30, Recruiting, Sponsor: Merrimack Pharmaceuticals
- Caprelsa (vandetanib) / Sanofi
Enrollment open, Stroma: Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Dec 13, 2013
P2, N=27, Recruiting, Sponsor: National Cancer Institute (NCI)
N=30 --> 39 Not yet recruiting --> Recruiting
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment closed, Metastases: A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma (clinicaltrials.gov) - Dec 12, 2013
P3, N=586, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Modufolin (arfolitixorin) / Isofol Medical, Solasia
Enrollment change: Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX. (clinicaltrials.gov) - Dec 11, 2013
P1/2, N=6, Not yet recruiting, Sponsor: Isofol Medical AB
Recruiting --> Active, not recruiting N=12 --> 6
- imetelstat (GRN163L) / Geron
New P2 trial: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Dec 11, 2013
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
- |||||||||| Kinaction (masitinib) / AB Science
New P3 trial, Surgery, Stroma: Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence (clinicaltrials.gov) - Dec 10, 2013
P3, N=330, Not yet recruiting, Sponsor: AB Science
- Votrient (pazopanib) / Novartis
Clinical: Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS (clinicaltrials.gov) - Dec 10, 2013
P=N/A, N=30, Recruiting, Sponsor: Radboud University
N=12 --> 6 Not yet recruiting --> Recruiting
- ganetespib (ADX-1612) / Aldeyra
New P1/2 trial, Combination therapy, Metastases: SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) (clinicaltrials.gov) - Dec 9, 2013
P1/2, N=38, Not yet recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
- Trial termination: Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer (clinicaltrials.gov) - Dec 9, 2013
P=N/A, N=2, Terminated, Sponsor: Stanford University
Not yet recruiting --> Recruiting Recruiting --> Terminated; Low accrual and no funding
- Enrollment change: Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer (clinicaltrials.gov) - Dec 9, 2013
P=N/A, N=2, Terminated, Sponsor: Stanford University
Recruiting --> Terminated; Low accrual and no funding N=20 --> 2
- | everolimus / Generic mfg.
New P2 trial: CHONRAD: A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas (clinicaltrials.gov) - Dec 9, 2013
P2, N=57, Not yet recruiting, Sponsor: Centre Leon Berard
- carotuximab IV (ENV-105) / Kairos Pharma
Enrollment open, Combination therapy, Metastases: A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Dec 8, 2013
P1b, N=18, Recruiting, Sponsor: Tracon Pharmaceuticals Inc.
N=20 --> 2 Not yet recruiting --> Recruiting
- Enrollment closed: Monitoring Chemotherapy Response of Soft Tissue Sarcomas and Osteosarcomas Using Diffuse Optical Spectroscopic Imaging (clinicaltrials.gov) - Dec 8, 2013
P=N/A, N=83, Active, not recruiting, Sponsor: Montana Compton
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | New P2 trial, Surgery: A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection (clinicaltrials.gov) - Dec 5, 2013
P2, N=132, Recruiting, Sponsor: Yale University
- Enrollment open, Surgery: A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection (clinicaltrials.gov) - Dec 5, 2013
P2, N=132, Recruiting, Sponsor: Yale University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- dasatinib / Generic mfg.
Enrollment closed: Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma (clinicaltrials.gov) - Dec 5, 2013
P2, N=113, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Suspended --> Active, not recruiting
- |||| albumin-bound paclitaxel / Generic mfg.
Enrollment open: Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors (clinicaltrials.gov) - Dec 4, 2013
P1/2, N=105, Recruiting, Sponsor: Celgene Corporation
Suspended --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| saridegib oral (IPI 926 oral) / Infinity Pharma
Trial completion, Metastases: A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma (clinicaltrials.gov) - Dec 3, 2013
P2, N=105, Completed, Sponsor: Infinity Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Sitoiganap (ERC1671) / Epitopoietic Research Corp
Enrollment change: ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme (clinicaltrials.gov) - Dec 2, 2013
P2, N=84, Recruiting, Sponsor: Daniela A. Bota
Active, not recruiting --> Completed N=70 --> 84
- || Vigil (gemogenovatucel-T) / Gradalis
Enrollment change, Tumor cell, Metastases: Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer (clinicaltrials.gov) - Dec 1, 2013
P1, N=60, Recruiting, Sponsor: Gradalis, Inc.
N=70 --> 84 N=40 --> 60
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Enrollment closed, Combination therapy: Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma (clinicaltrials.gov) - Dec 1, 2013
P2, N=100, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=40 --> 60 Recruiting --> Active, not recruiting
- Fragmin (dalteparin sodium) / Pfizer, Eisai, sunitinib / Generic mfg.
Enrollment closed, Combination therapy, Surgery, Metastases: Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Nov 26, 2013
P1, N=16, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Biomarker: 3T MRI Biomarkers of Glioma Treatment Response (clinicaltrials.gov) - Nov 25, 2013
P=N/A, N=22, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Metastases: Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors (clinicaltrials.gov) - Nov 25, 2013
P2, N=0, Completed, Sponsor: Societe Internationale d'Oncologie Pediatrique
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion, Surgery: Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Nov 25, 2013
P3, N=400, Completed, Sponsor: Societe Internationale d'Oncologie Pediatrique
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment change: Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer (clinicaltrials.gov) - Nov 21, 2013
P3, N=603, Recruiting, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed N=424 --> 603
- | Hiltonol (poly-ICLC) / Oncovir
Enrollment open: Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) (clinicaltrials.gov) - Nov 19, 2013
P2, N=20, Recruiting, Sponsor: Dr. Nina Bhardwaj
N=424 --> 603 Not yet recruiting --> Recruiting
- ||||| Enrollment closed, Metastases: High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma (clinicaltrials.gov) - Nov 19, 2013
P3, N=109, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Completed --> Active, not recruiting
- sorafenib / Generic mfg.
Enrollment change, Metastases: Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma (clinicaltrials.gov) - Nov 18, 2013
P2, N=147, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting N=222 --> 147
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment open, Combination therapy: Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) (clinicaltrials.gov) - Nov 18, 2013
P1/2, N=61, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=222 --> 147 Suspended --> Recruiting
- New P2 trial, Metastases: Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients With Metastatic Sarcoma Stable on Chemotherapy (clinicaltrials.gov) - Nov 17, 2013
P2, N=36, Not yet recruiting, Sponsor: Washington University School of Medicine
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
New P3 trial: Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer (clinicaltrials.gov) - Nov 17, 2013
P3, N=30, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
- ||||| Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
New P1/2 trial, Combination therapy, Stroma, Metastases: MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) (clinicaltrials.gov) - Nov 17, 2013
P1/2, N=62, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- Modufolin (arfolitixorin) / Isofol Medical, Solasia
New P1/2 trial: Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX. (clinicaltrials.gov) - Nov 17, 2013
P1/2, N=6, Not yet recruiting, Sponsor: Isofol Medical AB